Brainsway Ltd Sponsored ADR Stock

$8.50

3.41% today

Nasdaq, Sep 16, 08:18 pm CET

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Brainsway Ltd Sponsored ADR Stock price

$8.22

-2.28 21.71% 5Y

Nasdaq, Closing price Fri, Sep 13 2024

+0.17 2.11%

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$137.09m
Enterprise Value	$93.32m
P/E (TTM) P/E ratio	225.21
EV/FCF (TTM) EV/FCF	16.01
EV/Sales (TTM) EV/Sales	2.56
P/S ratio (TTM) P/S ratio	3.76
P/B ratio (TTM) P/B ratio	3.19
Revenue growth (TTM) Revenue growth	42.00%
Revenue (TTM) Revenue	$36.43m
EBIT (operating result TTM) EBIT	$730.00k
Free Cash Flow (TTM) Free Cash Flow	$5.83m
Cash position	$48.14m
EPS (TTM) EPS	$0.04
P/E forward	negative
P/S forward	3.46
EV/Sales forward	2.36
Short interest	0.43%

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Brainsway Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

4x Buy

100%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Brainsway Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '23		+/- %
Revenue	32 32	17% 17% 100%
- Direct Costs	8.69 8.69	29% 29% 27%
Gross Profit	23 23	13% 13% 73%
- Selling and Administrative Expenses	20 20	13% 13% 63%
- Research and Development Expense	6.53 6.53	14% 14% 21%
EBITDA	-3.59 -3.59	65% 65% -11%
- Depreciation and Amortization	1.34 1.34	13% 13% 4%
EBIT (Operating Income) EBIT	-4.93 -4.93	58% 58% -16%
Net Profit	-4.20 -4.20	69% 69% -13%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Brainsway Ltd Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about 8 hours ago

BrainsWay Announces Significant Expansion on U.S. East Coast

BURLINGTON, Mass. and JERUSALEM, Sept.

Neutral

GlobeNewsWire

●

6 days ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the Israel Ministry of Defense's Rehabilitation Department has granted approval for the reimbursement of Deep Transcranial Magnetic St...

Neutral

GlobeNewsWire

●

18 days ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field

More Brainsway Ltd Sponsored ADR News

Company Profile

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Head office	Israel
CEO	Hadar Levy
Employees	106
Founded	2006
Website	www.brainsway.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now